The janus facet of nanomaterials

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Kardos, Julianna ^a   Jemnitz, Katalin ^a   Jablonkai, István ^a   Bóta, Attila ^a   Varga, Zoltán ^a   Visy, Júlia ^a   Héja, László ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; DENDRIMER; LIPOSOME; NANOMATERIAL; POLYGLACTIN;

ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; NONHUMAN; TISSUE DISTRIBUTION; TOXICITY; ANIMAL; BRAIN; CHEMISTRY; HUMAN; LIVER; MATERIALS TESTING; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; BRAIN; HUMANS; LIVER; MATERIALS TESTING; NANOSTRUCTURES;

EID: 84930620488     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/317184     Document Type: Article

References (90)

1. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), "European Commission Health & Consumer Protection Directorate-General Directorate C (2006)-Public Health and Risk Assessment C7-Risk assessment," http://ec.europa.eu/health/scientific committees/ emerging/index en.htm.
2. S. S.Mukhopadhyay, "Nanotechnology in agriculture: prospects and constraints," Journal of Nanotechnology, Science and Applications, vol. 7, pp. 63-71, 2014.
3. L. Liu, S. Ouyang, and J. Ye, "Gold-nanorod-photosensitized titanium dioxide with wide-range visible-light harvesting based on localized surface plasmon resonance," Angewandte Chemie-International Edition, vol. 52, no. 26, pp. 6689-6693, 2013.
4. S. Prasad, "Nanobiosensors: the future for diagnosis of disease?" Nanobiosensors in Disease Diagnosis, vol. 3, pp. 1-10, 2014.
5. M. S. Singh and S. Bhaskar, "Nanocarrier-based immunotherapy in cancer management and research," ImmunoTargets and Therapy, vol. 3, pp. 121-134, 2014.
6. C. Wang, M. Osada, Y. Ebina et al., "All-nanosheet ultrathin capacitors assembled layer-by-layer via solution-based processes," ACS Nano, vol. 8, no. 3, pp. 2658-2666, 2014.
7. R. M. Crist, J. H. Grossman,A.K. Patri et al., "Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory," Integrative Biology, vol. 5, no. 1, pp. 66-73, 2013.
8. V. Stone, S. Pozzi-Mucelli, L. Tran et al., "ITS-NANO-prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy," Particle and Fibre Toxicology, vol. 11, no. 1, article 9, 2014.
9. R. Du, T. Zhong, W.-Q. Zhang et al., "Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma," International Journal of Nanomedicine, vol. 9, pp. 3091-3105, 2014.
10. P. Johansson, R. Jimbo, P. Kjellin, F. Fredrik Currie, B. R. Chrcanovic, and A. Wennerberg, "Biomechanical evaluation and surface characterization of a nano-modified surface on PEEK implants: a study in the rabbit tibia," International Journal of Nanomedicine, vol. 9, pp. 3903-3911, 2014.
11. G. Nyitrai, O. Kékesi, I. Pál et al., "Assessing toxicity of polyamidoamine dendrimers by neuronal signaling functions," Nanotoxicology, vol. 6, no. 6, pp. 576-586, 2012.
12. G. Nyitrai, L. Héja, I. Jablonkai, I. Pál, J. Visy, and J. Kardos, "Polyamidoamine dendrimer impairs mitochondrial oxidation in brain tissue," Journal of Nanobiotechnology, vol. 11, no. 1, article 9, 2013.
13. G. Nyitrai, T. Keszthelyi, A. Bóta et al., "Sodium selective ion channel formation in living cell membranes by polyamidoamine dendrimer," Biochimica et Biophysica Acta: Biomembranes, vol. 1828, no. 8, pp. 1873-1880, 2013.
14. X. Rong, W. Yuan, Y. Lu, and X. Mo, "Safety evaluation of poly(lactic-co-glycolic acid)/poly-(lactic-acid) microspheres through intravitreal injection in rabbits," International Journal of Nanomedicine, vol. 9, pp. 3057-3068, 2014.
15. E. Sawosz, S. Jaworski, M. Kutwin et al., "Toxicity of pristine graphene in experiments in a chicken embryo model," International Journal of Nanomedicine, vol. 9, pp. 3913-3922, 2014.
16. E. Seydoux, B. Rothen-Rutishauser, I. M. Nita et al., "Sizedependent accumulation of particles in lysosomes modulates dendritic cell function through impaired antigen degradation," International Journal of Nanomedicine, vol. 9, pp. 3885-3902, 2014.
17. T. Shokuhfar, A. Hamlekhan, J.-Y. Chang, C. K. Choi, C. Sukotjo, and C. Friedrich, "Biophysical evaluation of cells on nanotubular surfaces: the effects of atomic ordering and chemistry," International Journal of Nanomedicine, vol. 9, pp. 3737-3748, 2014.
18. L.Wang, C.Wang, J. Jiao et al., "Tolerance-like innate immunity and spleen injury: a novel discovery via the weekly administrations and consecutive injections of PEGylated emulsions," International Journal of Nanomedicine, vol. 9, pp. 3645-3657, 2014.
19. S. Wang, Y. Li, J. Fan et al., "The role of autophagy in the neurotoxicity of cationic PAMAM dendrimers," Biomaterials, vol. 35, pp. 7588-7597, 2014.
20. X. Xue, X. Chen, X. Mao et al., "Amino-terminated generation 2 poly(amidoamine) dendrimer as a potential broad-spectrum, nonresistance-inducing antibacterial agent,"The AAPS Journal, vol. 15, no. 1, pp. 132-142, 2013.
21. Y. Xue, Q. Chen, T. Ding, and J. Sun, "SiO2 nanoparticleinduced impairment of mitochondrial energy metabolism in hepatocytes directly and through a Kupffer cell-mediated pathway in vitro," International Journal of Nanomedicine, vol. 9, pp. 2891-2903, 2014.
22. C. Zhang,Q. Zhu, Y. Zhou et al., "N-Succinyl-chitosan nanoparticles coupled with low-density lipoprotein for targeted osthole-loaded delivery to low-density lipoprotein receptor-rich tumors," International Journal ofNanomedicine, vol. 9, pp. 2919-2932, 2014.
23. E. van der Pol, A. N. Böing, P. Harrison, A. Sturk, and R. Nieuwland, "Classification, functions, and clinical relevance of extracellular vesicles," Pharmacological Reviews, vol. 64, no. 3, pp. 676-705, 2012.
24. A. Danielyan, Y.-W. Wu, P.-Y. Shih, Y. Dembitskaya, and A. Semyanov, "Denoising of two-photon fluorescence images with Block-Matching 3D filtering," Methods, vol. 68, no. 2, pp. 308-316, 2014.
25. L. Pascolo, B. Bortot, N. Benseny-Cases et al., "Detection of PLGA-based nanoparticles at a single-cell level by synchrotron radiation FTIR spectromicroscopy and correlation with X-ray fluorescence microscopy," International Journal of Nanomedicine, vol. 9, pp. 2791-2801, 2014.
26. G. Goerigk and Z. Varga, "Comprehensive upgrade of the highresolution small-angle neutron scattering instrument KWS-3 at FRM II," Journal of Applied Crystallography, vol. 44, no. 2, pp. 337-342, 2011.
27. Z. Varga, A.Wacha, U. Vainio, J. Gummel, and A. Bóta, "Characterization of the PEG layer of sterically stabilized liposomes: a SAXS study," Chemistry and Physics of Lipids, vol. 165, no. 4, pp. 387-392, 2012.
28. Z. Varga, A. Wacha, and A. Bóta, "Osmotic shrinkage of sterically stabilized liposomes as revealed by time-resolved smallangle X-ray scattering," Journal of Applied Crystallography, vol. 47, part 1, pp. 35-40, 2014.
29. D.-M. Tang,D.G.Kvashnin, S.Najmaei et al., "Nanomechanical cleavage of molybdenum disulphide atomic layers," Nature Communications, vol. 5, article 4631, 2014.
30. S. Arora, S. K. Swaminathan, A. Kirtane et al., "Synthesis, characterization, and evaluation of poly (D,L-lactide-coglycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy," International Journal of Nanomedicine, vol. 9, pp. 2933-2942, 2014.
31. B. Balakrishnan, E. Nance, M. V. Johnston, R. Kannan, and S. Kannan, "Nanomedicine in cerebral palsy," International Journal of Nanomedicine, vol. 8, pp. 4183-4195, 2013.
32. B. V. Bonifácio, P. B. da Silva, M. A. dos Santos Ramos, K. M. N. Negri, T. M. Bauab, and M. Chorilli, "Nanotechnologybased drug delivery systems and herbal medicines: a review," International Journal of Nanomedicine, vol. 9, no. 1, pp. 1-15, 2013.
33. F. Danhier, E. Ansorena, J. M. Silva, R. Coco, A. Le Breton, and V. Préat, "PLGA-based nanoparticles: an overview of biomedical applications," Journal of Controlled Release, vol. 161, no. 2, pp. 505-522, 2012.
34. J.-J. Yao, Y.-Z.Du, J. You, H. Yuan, and F.-Q.Hu, "Efficient gene delivery system mediated by cis-aconitate-modified chitosang-stearic acid micelles," International Journal of Nanomedicine, vol. 9, no. 1, pp. 2993-3003, 2014.
35. L. Albertazzi, L. Gherardini, M. Brondi et al., "In vivo distribution and toxicity of PAMAM dendrimers in the central nervous system depend on their surface chemistry," Molecular Pharmaceutics, vol. 10, no. 1, pp. 249-260, 2013.
36. E. Fröhlich, "The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles," International Journal of Nanomedicine, vol. 7, pp. 5577-5591, 2012.
37. J. B. Pryor, B. J. Harper, and S. L. Harper, "Comparative toxicological assessment of PAMAM and thiophosphoryl dendrimers using embryonic zebrafish," International Journal of Nanomedicine, vol. 9, no. 1, pp. 1947-1956, 2014.
38. G.M.Ryan, L. M. Kaminskas, J. B. Bulitta, M. P. McIntosh,D. J. Owen, and C. J. H. Porter, "PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin," Journal of Controlled Release, vol. 172, no. 1, pp. 128-136, 2013.
39. R. Langer and D. A. Tirrell, "Designing materials for biology and medicine," Nature, vol. 428, no. 6982, pp. 487-492, 2004.
40. H.-I. Chang and M.-K. Yeh, "Clinical development of liposomebased drugs: formulation, characterization, and therapeutic efficacy," International Journal of Nanomedicine, vol. 7, pp. 49-60, 2012.
41. W. Jiang, R. Lionberger, and L. X. Yu, "In vitro and in vivo characterizations of PEGylated liposomal doxorubicin," Bioanalysis, vol. 3, no. 3, pp. 333-344, 2011.
42. J. Szebeni, "Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity," Toxicology, vol. 216, no. 2-3, pp. 106-121, 2005.
43. Y. Ohya, M. Shiratani, H. Kobayashi, and T. Ouchi, "Release behavior of 5-fluorouracil from chitosan-gel nanospheres immobilizing 5-fluorouracil coated with polysaccharides and their cell specific cytotoxicity," Journal of Macromolecular Science Part A: Pure and Applied Chemistry, vol. 31, no. 5, pp. 629-642, 1994.
44. Y. Hu, Y. Ding, D. Ding et al., "Hollow chitosan/poly(acrylic acid) nanospheres as drug carriers," Biomacromolecules, vol. 8, no. 4, pp. 1069-1076, 2007.
45. J. Zhang, X. G. Chen, Y. Y. Li, and C. S. Liu, "Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin," Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 3, no. 4, pp. 258-265, 2007.
46. Y.-S. Wang, Q. Jiang, R.-S. Li et al., "Self-assembled nanoparticles of cholesterol-modified O-carboxymethyl chitosan as a novel carrier for paclitaxel," Nanotechnology, vol. 19, no. 14, Article ID 145101, 2008.
47. K. H. Min, K. Park, Y.-S. Kim et al., "Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy," Journal of Controlled Release, vol. 127, no. 3, pp. 208-218, 2008.
48. L. Illum, "Chitosan and its use as a pharmaceutical excipient," Pharmaceutical Research, vol. 15, no. 9, pp. 1326-1331, 1998.
49. M. N. V. R. Kumar, R. A. A. Muzzarelli, C. Muzzarelli, H. Sashiwa, and A. J. Domb, "Chitosan chemistry and pharmaceutical perspectives," Chemical Reviews, vol. 104, no. 12, pp. 6017-6084, 2004.
50. R. P. McGeary, I. Jablonkai, and I. Toth, "Carbohydrate-based templates for synthetic vaccines and drug delivery," Tetrahedron, vol. 57, no. 41, pp. 8733-8742, 2001.
51. J. H. Park, G. Saravanakumar, K. Kim, and I. C. Kwon, "Targeted delivery of low molecular drugs using chitosan and its derivatives," Advanced Drug Delivery Reviews, vol. 62, no. 1, pp. 28-41, 2010.
52. T. Kean and M. Thanou, "Biodegradation, biodistribution and toxicity of chitosan," Advanced Drug Delivery Reviews, vol. 62, no. 1, pp. 3-11, 2010.
53. N. G. M. Schipper, K. M. Varum, and P. Artursson, "Chitosans as absorption enhancers for poorly absorbable drugs. 1: influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells," Pharmaceutical Research, vol. 13, no. 11, pp. 1686-1692, 1996.
54. N. G. M. Schipper, K. M. Varum, P. Stenberg, G. Ocklind, H. Lennernäs, and P. Artursson, "Chitosans as absorption enhancers of poorly absorbable drugs. 3: influence of mucus on absorption enhancement," European Journal of Pharmaceutical Sciences, vol. 8, no. 4, pp. 335-343, 1999.
55. S. B. Rao and C. P. Sharma, "Use of chitosan as a biomaterial: studies on its safety and hemostatic potential," Journal of Biomedical Materials Research, vol. 34, no. 1, pp. 21-28, 1997.
56. Y. Kato, H. Onishi, and Y.MacHida, "Evaluation of N-succinylchitosan as a systemic long-circulating polymer," Biomaterials, vol. 21, no. 15, pp. 1579-1585, 2000.
57. K. Tømmeraas, S. P. Strand, W. Tian, L. Kenne, and K. M. Varum, "Preparation and characterisation of fluorescent chitosans using 9-anthraldehyde as fluorophore," Carbohydrate Research, vol. 336, no. 4, pp. 291-296, 2001.
58. H.Karatas,Y. Aktas,Y.Gursoy-Ozdemir et al., "Ananomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection," Journal of Neuroscience, vol. 29, no. 44, pp. 13761-13769, 2009.
59. S. Bayod, J. del Valle, C. Pelegri et al., "Macroautophagic process was differentially modulated by long-term moderate exercise in rat brain and peripheral tissues," Journal of Physiology and Pharmacology, vol. 65, no. 2, pp. 229-239, 2014.
60. S. Palasubramaniam, S. Muniandy, and P. Navaratnam, "Resistance to extended-spectrum β-lactams by the emergence of SHV-12 and the loss of OmpK35 in Klebsiella pneumoniae and Escherichia coli in Malaysia," Journal of Microbiology, Immunology and Infection, vol. 42, no. 2, pp. 129-133, 2009.
61. N. Bertrand and J.-C. Leroux, "The journey of a drug-carrier in the body: an anatomo-physiological perspective," Journal of Controlled Release, vol. 161, no. 2, pp. 152-163, 2012.
62. H.Kettiger, A. Schipanski,P.Wick, andJ.Huwyler, "Engineered nanomaterial uptake and tissue distribution: fromcell to organism," International Journal of Nanomedicine, vol. 8, pp. 3255-3269, 2013.
63. S.-D. Li and L. Huang, "Pharmacokinetics and biodistribution of nanoparticles," Molecular Pharmaceutics, vol. 5, no. 4, pp. 496-504, 2008.
64. J. E. Riviere, "Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum dots," Wiley Interdisciplinary Reviews:Nanomedicine andNanobiotechnology, vol. 1, no. 1, pp. 26-34, 2009.
65. T. Ishihara, M. Takeda, H. Sakamoto et al., "Accelerated blood clearance phenomenon upon repeated injection of pegmodified pla-nanoparticles," Pharmaceutical Research, vol. 26, no. 10, pp. 2270-2279, 2009.
66. R. S. H. Yang, L. W. Chang, J.-P. Wu et al., "Persistent tissue kinetics and redistribution of nanoparticles, quantum Dot 705, in Mice: ICP-MS quantitative assessment," Environmental Health Perspectives, vol. 115, no. 9, pp. 1339-1343, 2007.
67. S. Yamago,H. Tokuyama, E.Nakamura et al., "In vivo biological behavior of a water-miscible fullerene: 14C labeling, absorption, distribution, excretion and acute toxicity," Chemistry and Biology, vol. 2, no. 6, pp. 385-389, 1995.
68. N. Kotagiri and J.-W. Kim, "Stealth nanotubes: strategies of shielding carbon nanotubes to evade opsonization and improve biodistribution," International Journal of Nanomedicine, vol. 9, no. 1, pp. 85-105, 2014.
69. M. K. Mishra, C. A. Beaty, W. G. Lesniak et al., "Dendrimer brain uptake and targeted therapy for brain injury in a large animal model of hypothermic circulatory arrest," ACS Nano, vol. 8, no. 3, pp. 2134-2147, 2014.
70. S. B. Pehlivan, "Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases," Pharmaceutical Research, vol. 30, no. 10, pp. 2499-2511, 2013.
71. I. Lynch and K. A.Dawson, "Protein-nanoparticle interactions," Nano Today, vol. 3, no. 1-2, pp. 40-47, 2008.
72. P. Aggarwal, J. B. Hall, C. B. McLeland, M. A. Dobrovolskaia, and S. E. McNeil, "Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy," Advanced Drug Delivery Reviews, vol. 61, no. 6, pp. 428-437, 2009.
73. S. Tenzer, D. Docter, J. Kuharev et al., "Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology," Nature Nanotechnology, vol. 8, no. 10, pp. 772-781, 2013.
74. E. Fröhlich, J. S.Mandeville, C. J. Jennings, R. Sedaghat-Herati, and H. A. Tajmir-Riahi, "Dendrimers bind human serum albumin," Journal of Physical Chemistry B, vol. 113, no. 19, pp. 6986-6993, 2009.
75. D. Shcharbin, B. Klajnert, V. Mazhul, and M. Bryszewska, "Dendrimer interactions with hydrophobic fluorescent probes and human serumalbumin," Journal of Fluorescence, vol. 15, no. 1, pp. 21-28, 2005.
76. C. Domonkos, I. Fitos, J. Visy, and F. Zsila, "Fatty acid modulated human serum albumin binding of the β-carboline alkaloids norharmane and harmane,"Molecular Pharmaceutics, vol. 10, no. 12, pp. 4706-4716, 2013.
77. I. Fitos, Á. Simon, F. Zsila et al., "Characterization of binding mode of imatinib to human α 1-acid glycoprotein," International Journal of BiologicalMacromolecules, vol. 50, no. 3, pp. 788-795, 2012.
78. X. Pan, J. Liu, T. Nguyen et al., "The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calciumuniporter," Nature Cell Biology, vol. 15, no. 12, pp. 1464-1472, 2013.
79. R. Kovács, I. Papageorgiou, and U. Heinemann, "Slice cultures as a model to study neurovascular coupling and blood brain barrier in vitro," Cardiovascular Psychiatry and Neurology, vol. 2011, Article ID 646958, 9 pages, 2011.
80. J.-S. Liu, J.-H.Wang, J. Zhou et al., " Enhanced brain delivery of lamotrigine with Pluronic P123-based nanocarrier," International Journal of Nanomedicine, vol. 9, pp. 3923-3935, 2014.
81. O. Butovsky, M. P. Jedrychowski, C. S. Moore et al., "Identification of a unique TGF-β-dependent molecular and functional signature in microglia," Nature Neuroscience, vol. 17, no. 1, pp. 131-143, 2014.
82. S. M. C. Smith, G. S. Mitchell, S. A. Friedle, C. M. Sibigtroth, S. Vinit, and J. J. Watters, "Hypoxia attenuates purinergic P2X receptor-induced inflammatory gene expression in brainstem microglia," Hypoxia, vol. 1, pp. 1-11, 2013.
83. M. Szabó, Z. Veres, A. Bátai-Konczos et al., "Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes," Toxicology in Vitro, vol. 28, no. 6, pp. 1136-1143, 2014.
84. K. Jemnitz, Z. Veres, R. Tugyi, and L. Vereczkey, "Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes," Toxicology in Vitro, vol. 24, no. 2, pp. 605-610, 2010.
85. K. Jemnitz, Z. Veres, and L. Vereczkey, "Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human," Toxicological Sciences, vol. 115, no. 1, pp. 80-88, 2010.
86. J. Wan, M. Benkdane, F. Teixeira-Clerc et al., "M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease," Hepatology, vol. 59, no. 1, pp. 130-142, 2014.
87. Z. Erdei, R. Lorincz, K. Szebényi et al., "Expression pattern of the human ABC transporters in pluripotent embryonic stem cells and in their derivatives," Cytometry Part B: Clinical Cytometry, vol. 86, no. 5, pp. 299-310, 2014.
88. Á. Telbisz, C. Hegedüs, A. Váradi, B. Sarkadi, and C. Özvegy-Laczka, "Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations in potential substrate and steroid binding sites," Drug Metabolism and Disposition, vol. 42, no. 4, pp. 575-585, 2014.
89. M. Rahman, S. Laurent, N. Tawil, L. Yahia, and M. Mahmoudi, "Nanoparticle and protein corona. Chapter 2 in Protein-Nanoparticle Interactions," in Protein-Nanoparticle Interactions, vol. 15 of The Bio-Nano Interface, Springer Series in Biophysics, pp. 21-44, Springer, Berlin, Germany, 2013.
90. P. del Pino, B. Pelaz, Q. Zhang, P. Maffre, G. U. Nienhaus, and W. J. Parak, "Protein corona formation around nanoparticlesfrom the past to the future," Material Horizons, vol. 1, no. 3, pp. 301-313, 2014.